Gesek Andrew 4
4 · Petros Pharmaceuticals, Inc. · Filed Dec 3, 2020
Insider Transaction Report
Form 4
Gesek Andrew
President, Timm Medical
Transactions
- Award
Common Stock, par value $0.0001 per share
2020-12-01+97→ 97 total(indirect: By LLC)
Footnotes (1)
- [F1]Received in exchange for 196.43 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Gesek's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share.